近期心肌梗死后急性缺血性卒中的静脉溶栓:病例系列与系统综述
本研究回顾性分析2家三级医院连续收治的急性缺血性卒中合并3个月内MI患者,并结合系统文献综述,比较接受与未接受标准剂量IV r-tPA治疗者的心脏并发症。溶栓组4例(8.5%)死于确诊或推测的心脏破裂/压塞,均发生于卒中前1周内发生STEMI者,非溶栓组1例(1.8%)发生该并发症(P=0.178)。结论提示决策需考虑MI类型及两事件间隔时间。
要点
- 近期非STEMI或同时事件者接受IV r-tPA可能安全。
- 卒中前1周内发生STEMI者溶栓需警惕心脏破裂/压塞。
- 需结合MI类型与两事件间隔时间个体化决策。
核心结论
- 急性缺血性卒中合并近期或同时MI时,决定IV r-tPA应综合考虑MI类型及两事件间隔时间。
- 近期非STEMI或同时事件似乎安全,但卒中前1周内STEMI应引起警惕。
研究设计与样本
- 回顾性分析2家三级大学医院连续收治的急性缺血性卒中合并前3个月内MI患者,并进行系统文献综述。
- 按是否接受标准剂量IV r-tPA分为两组,比较心脏并发症。
主要发现
- 溶栓组4例(8.5%)死于确诊或推测的心脏破裂/压塞,均发生于卒中前1周内发生STEMI者;非溶栓组1例(1.8%)发生该并发症(P=0.178)。
- 两组血栓栓塞(1例[2.1%] vs 2例[3.6%];P=1.000)和危及生命的心律失常(3例[6.4%] vs 7例[12.7%];P=0.335)无差异。
- 接受IV r-tPA的非STEMI患者未发生心脏并发症。
临床怎么用
- 对急性缺血性卒中合并近期MI患者,溶栓前应评估MI类型及距卒中时间。
- 对卒中前1周内发生STEMI者,应谨慎权衡溶栓获益与心脏破裂/压塞风险。
- 近期非STEMI或同时事件者可考虑IV r-tPA,但需个体化评估。
局限性
- 事件数量少,可能影响结论可靠性。
- 存在发表偏倚可能。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Background and Purpose- The safety of IV r-tPA (intravenous tissue-type plasminogen activator) for acute ischemic stroke (AIS) treatment after recent myocardial infarction (MI) is still a matter of debate. We studied the safety of delivering IV r-tPA to AIS patients with a MI within the preceding 3 months. Methods- Retrospective review of consecutive AIS admitted to 2 tertiary university hospitals' and systematic literature review for AIS patients with history of MI in the previous 3 months. Patients were divided into 2 groups: treated or not treated with standard IV r-tPA dose for AIS. Cardiac complications (cardiac rupture/tamponade, intracardiac thrombus embolization, or life-threatening arrhythmias) were compared between groups and assessed by type of MI (non-ST-segment-elevation myocardial infarction [STEMI], or STEMI) and time elapsed between vascular events. Results- One hundred and two patients were included; 46 (45.1%) were derived from literature review. Median age (interquartile range) was 64 (53-75) years old, and 69 (67.6%) were men. Forty-seven (46.1%) received IV r-tPA. In the treated group, 25 (53.2%) and 23 (48.9%) patients had, respectively, concurrent AIS and MI and STEMI, in comparison with 12 (21.8%; P=0.002) and 36 (65.5%; P=0.110) patients in the nontreated. Four (8.5%) IV r-tPA-treated patients died from confirmed or presumed cardiac rupture/ tamponade, all with a STEMI in the week preceding stroke. This complication occurred in 1 (1.8%) patients in the nontreated group (P=0.178). There were no differences in thrombus embolization (1 [2.1%) versus 2 [3.6]; P=1.000) and life-threatening arrhythmias (3 [6.4%) versus 7 [12.7]; P=0.335). No non-STEMI patients receiving IV r-tPA had cardiac complications. Conclusions- In patients with AIS and recent or concurrent MI, MI type and the time elapsed between the 2 events should be taken into consideration when deciding to deliver IV r-tPA. Although recent non-STEMI or concurrent events seem safe, STEMI in the week preceding stroke should prompt caution. The low number of events and publication bias may have influenced our conclusions.
引用
- Marto JP, Kauppila LA, Jorge C, et al. Intravenous Thrombolysis for Acute Ischemic Stroke After Recent Myocardial Infarction: Case Series and Systematic Review. Stroke. 2019. PMID: 31436141. doi:10.1161/STROKEAHA.119.025630
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。